Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
September 28 2020 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced the appointment of Jose “Pepe” Carmona as chief financial
officer. Pepe brings more than 20 years of experience in the
biopharmaceutical industry across numerous leadership roles,
geographies and therapeutic areas.
“Pepe joins Rubius Therapeutics during a period of excellent
progress as we dose escalate patients in our RTX-240 Phase 1 solid
tumor clinical trial, per plan, and initiate patient recruitment
for our RTX-240 Phase 1 relapsed/refractory acute myeloid leukemia
trial. We are on track to file an Investigational New Drug
application by year-end for our first artificial antigen-presenting
cell program, RTX-321, for the treatment of HPV-positive cancers,
and have a fully owned and operational manufacturing facility to
supply these clinical trials,” said Pablo J. Cagnoni, president and
chief executive officer. “Pepe’s extensive experience in global
finance and operations, as well as a track record of financing
clinical-stage and commercial biotech companies, will be critical
as we begin to generate clinical data and advance our broad
pipeline of potentially life-changing Red Cell Therapeutics™ for
the treatment of cancer and autoimmune diseases.”
Pepe most recently served as chief financial officer at Radius
Health, where he was responsible for all financial aspects of the
business as well as investor relations, business development and
other operational functions. Prior to joining Radius, Mr.
Carmona was chief financial officer of Innocoll
Holdings PLC, acquired by Gurnet Point L.P. During his career at
Novartis, Mr. Carmona held numerous financial management positions
with increasing responsibilities in various divisions as chief
financial officer in Europe, North America, Latin America and held
other senior global financial roles.
“I believe Rubius Therapeutics’ cutting-edge science and
pipeline of programs are poised to transform how cancer and
autoimmune diseases are treated,” said Pepe Carmona. “It is an
exciting time for Rubius, and I welcome the opportunity to join
this industry-leading leadership team and contribute towards
fostering the company’s further development.”
About Rubius Therapeutics
Rubius Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM®
genetically engineers and cultures Red Cell Therapeutics to create
selective, potent and off-the-shelf allogeneic cellular therapies
for the potential treatment of cancer and autoimmune diseases.
Rubius’ initial product candidates are designed to activate and
expand immune system function to fight cancer and modulate the
immune system to induce tolerance for the treatment of autoimmune
diseases. For more information, visit www.rubiustx.com, follow us
on Twitter or LinkedIn or like us on Facebook.Forward
Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the, our expectations regarding the therapeutic potential
of our Red Cell Therapeutics, including RTX-240 our expectations
regarding the timing, enrollment, data from and success of the
future cohorts and phases of the clinical trial of RTX-240, our
expectations regarding the therapeutic potential of RTX-321, the
timelines for us to file an IND for RTX-321, our expectations
regarding our strategy, business plans and focus and our
expectations in connection with the transition of our chief
financial officer. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential and other risks identified in our SEC
filings, including our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2020, and subsequent filings with the SEC
and risks and uncertainties related to the severity and duration of
the impact of COVID-19 on our business and operations. We caution
you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
Contacts:
InvestorsLori MelançonVice President, Corporate
Communications and Investor Relations+1 (617)
949-5296lori.melancon@rubiustx.com Media Marissa
HanifyDirector, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick1AB +1 (973)
271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024